Cereius

Cereius is a privately held preclinical-stage company developing novel approaches for the treatment of brain metastases in cancer. Cereius' innovative radiolabeled compounds increase the uptake and retention of radionuclides in target tumors while minimizing uptake in normal tissues, significantly enhancing the therapeutic index and diagnostic contrast of targeted agents.